Analytical and Bioanalytical Chemistry

, Volume 405, Issue 4, pp 1399–1406 | Cite as

Simultaneous and sensitive LC–MS/MS determination of tetrahydrocannabinol and metabolites in human plasma

  • N. Ferreirós
  • S. Labocha
  • C. Walter
  • J. Lötsch
  • G. Geisslinger
Original Paper

Abstract

Cannabis is not only a widely used illicit drug but also a substance which can be used in pharmacological therapy because of its analgesic, antiemetic, and antispasmodic properties. A very rapid and sensitive method for determination of ∆9-tetrahydrocannabinol (THC), the principal active component of cannabis, and two of its phase I metabolites in plasma has been developed and validated. After solid-phase extraction of plasma (0.2 mL), the clean extracts were analyzed by tandem mass spectrometry after a 5-min liquid chromatographic separation. The linear calibration ranges were from 0.05 to 30 ng mL−1 for THC and 11-nor-∆9-carboxy-tetrahydrocannabinol (THC-COOH) and from 0.2 to 30 ng mL−1 for ∆9-(11-OH)-tetrahydrocannabinol (11-OH-THC). Imprecision and inaccuracy were always below 7 and 12 % (expressed as relative standard deviation and relative error), respectively. The method has been successfully applied to determination of the three analytes in plasma obtained from healthy volunteers after oral administration of 20 mg dronabinol.

Keywords

THC Metabolites LC–MS/MS Cannabinoids 

Notes

Acknowledgments

This study was supported in part by the “Landesoffensive zur Entwicklung wissenschaftlich-ökonomischer Exzellenz: LOEWE. Schwerpunkt: Anwendungsorientierte Arzneimittelforschung” (GG, JL), the “Deutsche Forschungsgemeinschaft, DFG Lo 612/10-1 (JL)”, and the European Graduate School GRK757 (GG, JL).

References

  1. 1.
    EMCDDA (2011) The State of the Drugs Problem in Europe, Annual Report 2011. European Monitoring Centre for Drugs and Drug AddictionGoogle Scholar
  2. 2.
    Hall W, Degenhardt L (2009) Adverse health effects of non-medical cannabis use. Lancet 374:1383–1391CrossRefGoogle Scholar
  3. 3.
    Seely KA, Prather PL, James LP, Moran JH (2011) Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol Interv 11:36–51CrossRefGoogle Scholar
  4. 4.
    Husseini L, Leussink VI, Warnke C, Hartung HP, Kieseier BC (2011) Cannabinoids for symptomatic therapy of multiple sclerosis. Nervenarzt. doi: 10.1007/s00115-011-3401-9
  5. 5.
    Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I (2007) Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci 80:1415–1419CrossRefGoogle Scholar
  6. 6.
    Watanabe K, Matsunaga T, Yamamoto I, Funae Y, Yoshimura H (1995) Involvement of CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman. Biol Pharm Bull 18:1138–1141CrossRefGoogle Scholar
  7. 7.
    Richardson TH, Jung F, Griffin KJ, Wester M, Raucy JL, Kemper B, Bornheim LM, Hassett C, Omiecinski CJ, Johnson EF (1995) A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in Escherichia coli. Arch Biochem Biophys 323:87–96CrossRefGoogle Scholar
  8. 8.
    Schwope DM, Scheidweiler KB, Huestis MA (2011) Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography–tandem mass spectrometry. Anal Bioanal Chem 401:1273–1283CrossRefGoogle Scholar
  9. 9.
    Vree TB, Breimer DD, van Ginneken CA, van Rossum JM, de Zeeuw RA, Witte AH (1971) Identification of cannabivarins in hashish by a new method of combined gas chromatography–mass-spectrometry. Clin Chim Acta 34:365–372CrossRefGoogle Scholar
  10. 10.
    Mikes F, Hofmann A, Waser PG (1971) Identification of (−)-delta 9-6a,10a-trans-tetrahydrocannabinol and two of its metabolites in rats by use of combination gas chromatography–mass spectrometry and mass fragmentography. Biochem Pharmacol 20:2469–2476CrossRefGoogle Scholar
  11. 11.
    Breindahl T, Andreasen K (1999) Determination of 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid in urine using high-performance liquid chromatography and electrospray ionization mass spectrometry. J Chromatogr B: Biomed Sci Appl 732:155–164CrossRefGoogle Scholar
  12. 12.
    Backstrom B, Cole MD, Carrott MJ, Jones DC, Davidson G, Coleman K (1997) A preliminary study of the analysis of cannabis by supercritical fluid chromatography with atmospheric pressure chemical ionisation mass spectroscopic detection. Sci Justice 37:91–97CrossRefGoogle Scholar
  13. 13.
    Elian AA, Hackett J (2009) Solid-phase extraction and analysis of THC and carboxy-THC from whole blood using a novel fluorinated solid-phase extraction sorbent and fast liquid chromatography–tandem mass spectrometry. J Anal Toxicol 33:461–468Google Scholar
  14. 14.
    del Mar Ramirez Fernandez M, de Boeck G, Wood M, Lopez-Rivadulla M, Samyn N (2008) Simultaneous analysis of THC and its metabolites in blood using liquid chromatography–tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 875:465–470CrossRefGoogle Scholar
  15. 15.
    Valiveti S, Hammell DC, Earles DC, Stinchcomb AL (2005) LC–MS method for the estimation of delta8-THC and 11-nor-delta8-THC-9-COOH in plasma. J Pharm Biomed Anal 38:112–118CrossRefGoogle Scholar
  16. 16.
    de Jager AD, Bailey NL (2011) Online extraction LC-MS/MS method for the simultaneous quantitative confirmation of urine drugs of abuse and metabolites: amphetamines, opiates, cocaine, cannabis, benzodiazepines and methadone. J Chromatogr B Anal Technol Biomed Life Sci 879:2642–2652CrossRefGoogle Scholar
  17. 17.
    Grauwiler SB, Scholer A, Drewe J (2007) Development of a LC/MS/MS method for the analysis of cannabinoids in human EDTA-plasma and urine after small doses of Cannabis sativa extracts. J Chromatogr B Anal Technol Biomed Life Sci 850:515–522CrossRefGoogle Scholar
  18. 18.
    Gray TR, Barnes AJ, Huestis MA (2010) Effect of hydrolysis on identifying prenatal cannabis exposure. Anal Bioanal Chem 397:2335–2347CrossRefGoogle Scholar
  19. 19.
    Konig S, Aebi B, Lanz S, Gasser M, Weinmann W (2011) On-line SPE LC-MS/MS for the quantification of Delta9-tetrahydrocannabinol (THC) and its two major metabolites in human peripheral blood by liquid chromatography tandem mass spectrometry. Anal Bioanal Chem 400:9–16CrossRefGoogle Scholar
  20. 20.
    Jagerdeo E, Montgomery MA, Karas RP, Sibum M (2010) A fast method for screening and/or quantitation of tetrahydrocannabinol and metabolites in urine by automated SPE/LC/MS/MS. Anal Bioanal Chem 398:329–338CrossRefGoogle Scholar
  21. 21.
    Weinmann W, Goerner M, Vogt S, Goerke R, Pollak S (2001) Fast confirmation of 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (THC-COOH) in urine by LC/MS/MS using negative atmospheric-pressure chemical ionisation (APCI). Forensic Sci Int 121:103–107CrossRefGoogle Scholar
  22. 22.
    Weinmann W, Vogt S, Goerke R, Muller C, Bromberger A (2000) Simultaneous determination of THC-COOH and THC-COOH-glucuronide in urine samples by LC/MS/MS. Forensic Sci Int 113:381–387CrossRefGoogle Scholar
  23. 23.
    Felli M, Martello S, Chiarotti M (2011) LC-MS-MS method for simultaneous determination of THCCOOH and THCCOOH-glucuronide in urine: Application to workplace confirmation tests. Forensic Sci Int 204:67–73CrossRefGoogle Scholar
  24. 24.
    Chebbah C, Pozo OJ, Deventer K, Van Eenoo P, Delbeke FT (2010) Direct quantification of 11-nor-Delta(9)-tetrahydrocannabinol-9-carboxylic acid in urine by liquid chromatography/tandem mass spectrometry in relation to doping control analysis. Rapid Commun Mass Spectrom 24:1133–1141CrossRefGoogle Scholar
  25. 25.
    Teixeira H, Proenca P, Castanheira A, Santos S, Lopez-Rivadulla M, Corte-Real F, Marques EP, Vieira DN (2004) Cannabis and driving: the use of LC–MS to detect delta9-tetrahydrocannabinol (delta9-THC) in oral fluid samples. Forensic Sci Int 146(Suppl):S61–S63CrossRefGoogle Scholar
  26. 26.
    Molnar A, Lewis J, Doble P, Hansen G, Prolov T, Fu S (2011) A rapid and sensitive method for the identification of delta-9-tetrahydrocannabinol in oral fluid by liquid chromatography–tandem mass spectrometry. Forensic Sci Int. doi: 10.1016/j.forsciint.2011.01.045:
  27. 27.
    Walter C, Oertel BG, Felden L, Nöth U, Deichmann R, Lötsch J (2011) The effects of delta-9-tetrahydrocannabinol on nasal chemosensitivity: a pharmacological fMRI study in healthy volunteers. Naunyn Schmiedebergs Arch Pharmacol 383(Suppl 1):75Google Scholar
  28. 28.
    Guidance for Industry: Bioanalytical Method Validation (2001) US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research, Rockville, USA www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070107.pdf. Accessed 21 Jun 2012
  29. 29.
    Smith G (2010) Bioanalytical method validation: notable points in the 2009 draft EMA Guideline and differences with the 2001 FDA Guidance. Bioanalysis 2:929–935CrossRefGoogle Scholar
  30. 30.
    Validation of Analytical Procedures: Text and Methodology Q2(R1) (2005) ICH. International Conference on Harmonisation of Technical Requirements, ICH Harmonised Tripartite Guideline, Geneva, Switzerland. http://private.ich.org/LOB/media/MEDIA417.pdf. Accessed 21 Jun 2012
  31. 31.
    Matuszewski BK, Constanzer ML, Chavez-Eng CM (2003) Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 75:3019–3030CrossRefGoogle Scholar
  32. 32.
    Wall ME, Perez-Reyes M (1981) The metabolism of delta 9-tetrahydrocannabinol and related cannabinoids in man. J Clin Pharmacol 21:178S–189SGoogle Scholar
  33. 33.
    Grotenhermen F (2003) Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42:327–360CrossRefGoogle Scholar
  34. 34.
    Dubois N, Paccou AP, De Backer BG, Charlier CJ (2012) Validation of the quantitative determination of tetrahydrocannabinol and its two major metabolites in plasma by ultra-high-performance liquid chromatography–tandem mass spectrometry according to the total error approach. J Anal Toxicol 36:25–29CrossRefGoogle Scholar
  35. 35.
    Milman G, Schwope DM, Schwilke EW, Darwin WD, Kelly DL, Goodwin RS, Gorelick DA, Huestis MA (2011) Oral fluid and plasma cannabinoid ratios after around-the-clock controlled oral delta(9)-tetrahydrocannabinol administration. Clin Chem 57:1597–1606CrossRefGoogle Scholar
  36. 36.
    Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA (2011) Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem 57:66–75CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • N. Ferreirós
    • 1
  • S. Labocha
    • 1
  • C. Walter
    • 1
  • J. Lötsch
    • 1
  • G. Geisslinger
    • 1
  1. 1.Pharmazentrum Frankfurt/ZAFES, Institute of Clinical PharmacologyGoethe-University FrankfurtFrankfurt am MainGermany

Personalised recommendations